PAREXEL International Offers Proactive Approach to Drug Safety and Risk Management with Pharmacovigilance Services

BOSTON, June 14 /PRNewswire-FirstCall/ -- PAREXEL International Corporation , a leading global bio/pharmaceutical services organization, is helping its customers take a proactive approach to drug safety and risk management with its Pharmacovigilance Services. Bio/pharmaceutical companies work with PAREXEL's Pharmacovigilance Services to incorporate safety considerations and risk management into their drug development programs -- from the earliest stages where the most potential for benefit exists, through the entire development lifecycle.

"Bio/pharmaceutical companies today find themselves under escalating public scrutiny with respect to drug safety issues," says Mark A. Goldberg, M.D., President of Clinical Research Services and Perceptive Informatics, PAREXEL International. "Coupling that with the growing number of regulations and risk management commitments, and companies are facing a dramatic drug safety issue that can't be ignored."

Through PAREXEL's Pharmacovigilance Services customers have access to a global network of experts that can help weave the appropriate safety and risk management measures throughout the entire drug development process. These experts include safety physicians, scientists, and pharmacoepidemiologists as well as consultants that bring regulatory experience from leading Health Authorities, such as the FDA or the MHRA. Services include adverse event management, regulatory reporting, design and maintenance of global safety databases, coding, trend analysis, and risk management. The program continues across all phases of clinical development through launch and post-marketing surveillance. If desired, companies can effectively outsource their entire drug safety departments to PAREXEL.

"For a pharmacovigilance program to work, bio/pharmaceutical companies must lay a foundation of safety risk early on and manage it closely throughout the entire drug lifecycle," says Uwe Maennl, M.D., Ph.D., Vice President and Head, Pharmacovigilance Services, PAREXEL. "PAREXEL has focused significant effort on developing a comprehensive pharmacovigilance offering to help these companies reduce potential costly setbacks that can threaten both product revenues and reputation."

For more information, visit http://www.PAREXEL.com or visit us at the DIA 43rd Annual Meeting, booth #724.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 55 locations throughout 43 countries around the world, and has over 6,315 employees. For more information about PAREXEL International visit http://www.PAREXEL.com .

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets" and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward- looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2007 as filed with the SEC on May 9, 2007, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

Contacts: Karen Wills, Vice President, Corporate Marketing PAREXEL International Tel: +781-434-5301 Email: Karen.Wills@PAREXEL.com Rebecca Passo SHIFT Communications Tel: +617-779-1817 Email: rpasso@shiftcomm.com

PAREXEL International Corporation

CONTACT: Karen Wills, Vice President, Corporate Marketing of PAREXELInternational, +1-781-434-5301, Karen.Wills@PAREXEL.com; or Rebecca Passoof SHIFT Communications for PAREXEL International, +1-617-779-1817,rpasso@shiftcomm.com

Back to news